Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features.

Authors:
Wilkins CA; Hamman H; Hamman JH; Steenekamp JH.

Journal:
Pharmaceutics

Publication Year: 2024

DOI:
10.3390/pharmaceutics16020178

PMCID:
PMC10892518

PMID:
38399239

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Pharmaceutics

Abbreviation: Pharmaceutics

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
3D-Printed Alginate/Pectin-Based Patches Loaded with Olive Leaf Extracts for Wound Healing Applicat…
Patitucci F; Motta MF; Dattilo M and 8 more (2024) - Transparency Score: 3/6
3D Printing of Biodegradable Polymeric Microneedles for Transdermal Drug Delivery Applications.
Aldawood FK; Parupelli SK; Andar A and 1 more (2024) - Transparency Score: 3/6
4-(Phenylselanyl)-2H-chromen-2-one-Loaded Nanocapsule Suspension-A Promising Breakthrough in Pain M…
da Fonseca CAR; Prado VC; Paltian JJ and 10 more (2024) - Transparency Score: 4/6
A Bilayer Microarray Patch (MAP) for HIV Pre-Exposure Prophylaxis: The Role of MAP Designs and Form…
Vora LK; Tekko IA; Zanutto FV and 7 more (2024) - Transparency Score: 3/6
Acylation of Oleanolic Acid Oximes Effectively Improves Cytotoxic Activity in In Vitro Studies.
Bednarczyk-Cwynar B; Ruszkowski P. (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest The authors declare no conflicts of interest."

Evidence found in paper:

"This research was funded by the National Research Foundation of South Africa (Grant number RA191126494324). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and therefore the NRF does not accept any liability with regard thereto."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025